Leal T, et al. Identifying resistance to immune checkpoint inhibitors by screening for PD-L1 and MHC I expression on CTCS in pts with NSCLC. IASLC 2018; abstract P3.04-08.
Invloed antilichamen op pembrolizumab-monotherapie bij melanoom nog onduidelijk
mrt 2022 | Dermato-oncologie, Immuuntherapie